Published on Microbicide Trials Network (http://www.mtnstopshiv.org)

Home > HPTN 035 Study Specific Procedures (SSP)

HPTN 035 Study Specific Procedures (SSP)

DescriptionDateSize
HPTN 035 DAIDS SOP for Source Documentation [1]2002-Jul-31858.8 KB
HPTN 035 DAIDS SOP for Essential Documents [2]2002-Jul-31368.21 KB
Manual
HPTN 035 Overview and Version Control [3]2008-Apr-1726.64 KB
Section 01: Introduction [4]2007-Jan-31135.9 KB
Section 02: Protocol [5]2007-Jan-31792.86 KB
Section 03: Documentation Requirements [6]2007-Jan-31189.37 KB
Section 04: Participant Accrual [7]2007-Jan-31400.82 KB
Section 05: Informed Consent [8]2007-Jan-311.35 MB
Section 06: Participant Follow-up [9]2008-Apr-17298.56 KB
Section 07: Visit Checklists [10]2008-Mar-31543.02 KB
Section 08: Participant Retention [11]2007-Jan-31142.2 KB
Section 09: Study Product Considerations for Non-Pharmacy Staff [12]2007-Jan-31230.8 KB
Section 10: Clinical Considerations [13]2007-Nov-07197.97 KB
Section 11: Adverse Event Reporting and Safety Monitoring [14]2007-Jul-31400.17 KB
Section 12: Laboratory Considerations [15]2007-Nov-0799.59 KB
Section 13: Data Collection [16]2007-Jan-311.66 MB
Section 14: Data Communiques [17]2007-Jan-31351.95 KB
Section 15: Study Reporting Plan [18]2007-Jan-3132.49 KB
Printer-friendly version [19]
Source URL: http://www.mtnstopshiv.org/node/91

Links:
[1] http://www.mtnstopshiv.org/sites/default/files/attachments/SourceDocSOPv2.pdf
[2] http://www.mtnstopshiv.org/sites/default/files/attachments/EssentialDocSOPv2.pdf
[3] http://www.mtnstopshiv.org/sites/default/files/attachments/HPTN035StudySpecificProceduresManual041808.pdf
[4] http://www.mtnstopshiv.org/sites/default/files/attachments/Section01FINAL013107.pdf
[5] http://www.mtnstopshiv.org/sites/default/files/attachments/Section02FINAL013107.pdf
[6] http://www.mtnstopshiv.org/sites/default/files/attachments/Section03FINAL013107.pdf
[7] http://www.mtnstopshiv.org/sites/default/files/attachments/Section04FINAL013107.pdf
[8] http://www.mtnstopshiv.org/sites/default/files/attachments/Section05FINAL013107.pdf
[9] http://www.mtnstopshiv.org/sites/default/files/attachments/Section06FINAL041808.pdf
[10] http://www.mtnstopshiv.org/sites/default/files/attachments/Section07FINAL040108.pdf
[11] http://www.mtnstopshiv.org/sites/default/files/attachments/Section08FINAL013107.pdf
[12] http://www.mtnstopshiv.org/sites/default/files/attachments/Section09FINAL013107.pdf
[13] http://www.mtnstopshiv.org/sites/default/files/attachments/Section10FINAL110707.pdf
[14] http://www.mtnstopshiv.org/sites/default/files/attachments/Section11FINAL080107.pdf
[15] http://www.mtnstopshiv.org/sites/default/files/attachments/Section12FINAL110707.pdf
[16] http://www.mtnstopshiv.org/sites/default/files/attachments/Section13FINAL022807.pdf
[17] http://www.mtnstopshiv.org/sites/default/files/attachments/Section14FINAL110707.pdf
[18] http://www.mtnstopshiv.org/sites/default/files/attachments/Section15FINAL013107.pdf
[19] http://www.mtnstopshiv.org/print/91

Media Contacts:

Lisa Rossi -- Office: +1 412 641-8940 -- Mobile: +1 412 916-3315 -- Email: rossil@upmc.edu

Clare Collins -- Office: +1 412 641-7299 -- Mobile: +1 412 770-8643 -- Email: collcx@upmc.edu